Torray Investment Partners LLC Acquires 41,472 Shares of Royalty Pharma PLC $RPRX

Torray Investment Partners LLC increased its holdings in Royalty Pharma PLC (NASDAQ:RPRX) by 5.9% during the 4th quarter, HoldingsChannel reports. The fund owned 744,355 shares of the biopharmaceutical company’s stock after acquiring an additional 41,472 shares during the quarter. Royalty Pharma comprises approximately 4.1% of Torray Investment Partners LLC’s investment portfolio, making the stock its 2nd largest holding. Torray Investment Partners LLC’s holdings in Royalty Pharma were worth $28,762,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Private Trust Co. NA increased its holdings in Royalty Pharma by 52.9% in the fourth quarter. Private Trust Co. NA now owns 832 shares of the biopharmaceutical company’s stock valued at $32,000 after buying an additional 288 shares during the last quarter. Smartleaf Asset Management LLC increased its holdings in Royalty Pharma by 868.1% in the third quarter. Smartleaf Asset Management LLC now owns 881 shares of the biopharmaceutical company’s stock valued at $31,000 after buying an additional 790 shares during the last quarter. Financial Consulate Inc. bought a new stake in Royalty Pharma in the third quarter valued at about $35,000. Larson Financial Group LLC increased its holdings in Royalty Pharma by 31.9% in the third quarter. Larson Financial Group LLC now owns 1,264 shares of the biopharmaceutical company’s stock valued at $45,000 after buying an additional 306 shares during the last quarter. Finally, Richardson Financial Services Inc. bought a new stake in Royalty Pharma in the third quarter valued at about $54,000. 54.35% of the stock is owned by institutional investors.

Insider Activity at Royalty Pharma

In other news, CFO Terrance P. Coyne sold 114,954 shares of the company’s stock in a transaction that occurred on Tuesday, February 3rd. The stock was sold at an average price of $42.84, for a total transaction of $4,924,629.36. Following the completion of the transaction, the chief financial officer directly owned 23,972 shares of the company’s stock, valued at approximately $1,026,960.48. This represents a 82.74% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Marshall Urist sold 20,000 shares of the company’s stock in a transaction that occurred on Friday, January 30th. The shares were sold at an average price of $41.09, for a total value of $821,800.00. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 387,914 shares of company stock valued at $16,879,974 over the last ninety days. Corporate insiders own 18.84% of the company’s stock.

Analyst Ratings Changes

Several analysts recently weighed in on RPRX shares. Citigroup boosted their price objective on Royalty Pharma from $48.00 to $50.00 and gave the company a “buy” rating in a report on Tuesday, January 27th. TD Cowen reissued a “buy” rating on shares of Royalty Pharma in a report on Friday, February 27th. The Goldman Sachs Group reissued a “buy” rating on shares of Royalty Pharma in a report on Thursday, February 12th. Weiss Ratings raised Royalty Pharma from a “hold (c+)” rating to a “buy (b-)” rating in a report on Thursday, February 12th. Finally, Wall Street Zen lowered Royalty Pharma from a “strong-buy” rating to a “buy” rating in a report on Saturday, February 14th. Six investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $50.33.

Royalty Pharma Stock Performance

Shares of NASDAQ:RPRX traded down $0.17 during trading on Thursday, hitting $49.56. 245,553 shares of the company traded hands, compared to its average volume of 3,486,438. The stock has a market capitalization of $28.59 billion, a price-to-earnings ratio of 36.67, a PEG ratio of 3.16 and a beta of 0.39. The business’s fifty day moving average is $46.78 and its 200-day moving average is $41.84. Royalty Pharma PLC has a one year low of $31.58 and a one year high of $50.08. The company has a quick ratio of 2.40, a current ratio of 2.40 and a debt-to-equity ratio of 0.88.

Royalty Pharma (NASDAQ:RPRX) last posted its earnings results on Wednesday, February 11th. The biopharmaceutical company reported $1.46 EPS for the quarter, beating the consensus estimate of $1.33 by $0.13. The company had revenue of $621.99 million during the quarter, compared to analyst estimates of $839.97 million. Royalty Pharma had a return on equity of 28.21% and a net margin of 32.38%. As a group, equities analysts predict that Royalty Pharma PLC will post 5.08 earnings per share for the current fiscal year.

Royalty Pharma Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, June 10th. Stockholders of record on Friday, May 15th will be issued a dividend of $0.235 per share. The ex-dividend date of this dividend is Friday, May 15th. This represents a $0.94 annualized dividend and a dividend yield of 1.9%. Royalty Pharma’s dividend payout ratio is 69.63%.

Royalty Pharma Profile

Royalty Pharma plc is a specialty finance company that acquires biopharmaceutical royalty interests and provides non-dilutive financing to drug developers and rights holders. The firm purchases future royalty streams, milestone-contingent payments and other revenue rights linked to approved and late-stage pharmaceutical and biotechnology products. By paying upfront consideration for these rights, Royalty Pharma seeks to generate long-term cash flows tied to the commercial performance of a diversified portfolio of medicines.

The company’s transaction structures include outright royalty purchases, structured financings and milestone arrangements tailored to the needs of innovator companies, academic institutions and investors.